Physician profile
John N Mackey
NPI 1275609984
$18,340.76
in general payments reported to CMS, 2019-2025
54 companies · $3,559 in 2025
The $3,559 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,941 · 2022: $3,626 · 2023: $3,463 · 2024: $3,753 · 2025: $3,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $62.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,712.40 |
| Education | $62.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,156.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,874.59 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,789.65 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,331.74 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $1,179.18 | 2021-2025 | Ozempic, Rybelsus |
| Alkermes, INC. | $755.31 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $738.78 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $734.98 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $470.06 | 2022-2025 | Auvelity |
| Amgen INC. | $439.85 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $433.71 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $408.38 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $300.78 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $296.40 | 2021-2025 | Ztlido |
| Regeneron Healthcare Solutions, INC. | $292.30 | 2024-2025 | Dupixent |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.